Paraoxanase: Biochemical features, functions and clinical importance;Paraoksonaz: Bi̇yoki̇myasal özelli̇kleri̇, fonksi̇yonlari ve kli̇ni̇k önemi̇

Erciyes Tip Dergisi

Volumn 26, Issue 2, 2004, Pages 75-80

  Başkol, Gülden ^a   Köse, Kader ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Organophosphate; Paraoxonase

Indexed keywords

APOLIPOPROTEIN A1; ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; HYDROLASE; MESSENGER RNA; NEUROTOXIN; ORGANOPHOSPHATE INSECTICIDE;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME STABILITY; ENZYME SUBSTRATE COMPLEX; HUMAN; HYDROLYSIS; LIPID METABOLISM; LIPOPROTEIN METABOLISM; REVIEW; XENOBIOTIC METABOLISM;

EID: 4344620908     PISSN: 1300199X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Gan N, Smolen A, Eckerson W, La Du BN. 'Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos 1991; 19: 100-106.
2. Aldridge WN. Serum esterases. II. an enzyme hydrolysing diethyl p-nitrophenylphosphate (EGOO) and its identity with A-esterase of mammalian sera. Bichem J 1953; 53: 117-124.
3. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 2001; 21: 473-480.
4. Hegele RA. Paraoxonase genes and disease. Ann Med 1999; 31: 217-224
5. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN. The human serum paraoxonase/aryesterase gene (PON 1) is one member of a multigene family. Genomics 1996; 33: 498-507.
6. Draganov DI, Stetson PL, Wateon Ce, Billecke SS, La Du BN. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 2000; 275: 33435-33442.
7. La Du BN, Aviram M, Billecke S, et al. On the physiological role(s) of the paraoxonases. Chem Biol Interact 1999; 119-120: 379-388.
8. - Mackness MI, Halton SD, Pend T, Warner S, Walken CN. The seperation of sheep and human serum A-esterase activity with the lipoprotein fraction by ultracentrifugation. Biochem Physiol 1985; 82: 675-677.
9. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci USA 1995; 92: 7187-7191.
10. Blatter MC, James RW, Messmer J, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by lipoprotein subspecies defined by a lipoprotein-associated protein. K-85: Identify of K-85 with paraoxonase. Eur J Biochem 1993; 211: 871-879.
11. Humbert R, Adler DA, Disteche. CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum paraoxonase activity polymorhism. Nat Genet 1993; 40: 73-76.
12. - Rodrigo L, Hernandez F, Caballero L, Gil F, Pla A. Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 2001; 137: 123-137.
13. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101: 1581-1590.
14. Eckerson HW, Romson J, Wyte C, La Du BN. The Human serum paraoxonase polymorphism: Identification of phenotypes by their response to salts. Am J Hum Genet 1983; 35: 214-227.
15. Bilecke S, Draganov D, Counsell R, et al. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters. Drug Metab Dispos 2000; 28: 1335-1342.
16. Reiner E, Simeon V, Skrinjaric S. Hydrolysis of O,O-dimethyl-2,2- dichlorovinyl phosphate (DDVP) by esterases in parasitic helmints and in vertebrate plasma and erythrocytes. Comp Biochem Physiol 1980; 66: 149-152.
17. McCracken NW, Blain PG, Williams FM. Human xenobiotic metabolizing esterases in liver and blood. Biochem Pharmacol 1993; 46: 1125-1129.
18. Gonzalvo Mc, Gil F, Hernandez AF, Rodrigo L, Villanuave E, Pla A. Human liver paraoxonase (PON1): Subsellular distribution and characterization. J Biochem Mol Toxicol 1998; 12: 61-69.
19. Wallace KB, Dargan JE. Intrensek metabolic clerance of parathion and paraoxon by livers from fish and rodents. Toxicol Appl Pharmacol 1987; 90: 235-242.
20. Gil F, Pla A, Gonzalvo MC, Hernandez FA, Villanueva E. Rat liver paraoxonase: subsellular distribution and characterization. Chem Biol Interact 1993; 87: 149-154.
21. Rodrigo L, Gil F, Hernandez F, Marina A, Vazquez J, Pla A. Purification and characterization of paraoxon hydrolase from rat liver. Biochem J 1997; 321: 595-601.
22. Mackness MI. Human serum paraoxonase is inhibited in EDTA plasma. Biochem Biophys Res Commun 1998; 242: 249.
23. Gil F, Gonzalvo MC, Hernandez AF, Villanueva E, Pla A. Differences in the kinetic properties, effect of calcium and sensitivity to inhibitors of paraoxon hydrolase activity in rat plasma and microsomal fraction from rat liver. Biochem Pharmacol 1994; 48: 1559-1568.
24. Lock EA, Reed CJ. Xenobiotic metabolizing enzymes of the kidney. Toxicol Pathol 1998; 26: 18-25
25. Walker CH, Mackness MI. A-esterases and their role in regulating the toxicity of organophosphates. Arch Toxicol 1987; 60: 30-33
26. Hahn M, Subbiah MT. Significant association of lipid peroxidation products with high density lipoproteins. Biochem Mol Biol Int 1994; 33: 699-704.
27. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidised low density lipoprotein. J Clin Invest 1995; 96: 2882-2891.
28. La Du BN. Structural and functional diversity of paraoxonases, Nat Med 1996; 2: 1186-1187
29. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required against LDL oxidation involves itsfree sulfhydryl group and is different than that irequired for its arylesterase/paraoxonase activities: selective action for human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 1998; 18: 1617-1624.
30. Steinberg D. Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. New England J Med 1989; 320: 915-924.
31. Wilkins GM, Leae DS. The effect of free radical scavenger on the oxidation of low-density lipoproteins by macrophages. Biochim Biophys Acta 1994; 1215: 250-258.
32. Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis 1991; 86: 193-199.
33. Paragh G, Asztalos LK, Seres I, et al. Serum paraoxonase activity changes in uremic and kidney-transplanted patients. Nephron 1999; 83: 126-131.